Literature DB >> 33420141

Restoration of surfactant activity by polymyxin B in lipopolysaccharide-potentiated injury of immature rabbit lungs.

Andrea Calkovska1,2, Marie Haegerstrand-Björkman3, Tore Curstedt3.   

Abstract

During postnatal adaptation pulmonary surfactant may be inactivated by lipopolysaccharide (LPS). We evaluated the effect of surfactant therapy in combination with antibiotic polymyxin B (PxB) in double-hit model of neonatal lung injury. Surfactant (poractant alfa, Curosurf) was exposed to smooth (S) LPS without/with PxB and tested in captive bubble surfactometer. Preterm rabbits received intratracheally saline (control) or S-LPS and were ventilated with 100% oxygen. After 30 min, LPS-treated animals received no treatment, or surfactant (200 mg/kg) without/with 3% PxB; controls received the same dose of surfactant. Animals were ventilated for further 2 h. In vitro, addition of 5% S-LPS to surfactant increased minimum surface tension (γmin) and addition of 1-3% PxB to surfactant/S-LPS mixture restored γmin to low values. Animals only given S-LPS had lower lung compliance and lung gas volume (LGV) compared to surfactant groups. Treatment with surfactant/PxB, but not with surfactant only, restored LGV. Addition of PxB to the surfactant increased the alveolar expansion. S-LPS interferes with surface activity of the pulmonary surfactant and PxB improves the resistance of surfactant to LPS-induced inactivation. In our neonatal model of respiratory distress syndrome surfactant gives positive response even in simultaneous exposure to S-LPS, when enriched with PxB.

Entities:  

Year:  2021        PMID: 33420141      PMCID: PMC7794303          DOI: 10.1038/s41598-020-79679-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  40 in total

1.  Pulmonary surfactant protein B: a structural model and a functional analogue.

Authors:  S Zaltash; M Palmblad; T Curstedt; J Johansson; B Persson
Journal:  Biochim Biophys Acta       Date:  2000-06-01

2.  European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update.

Authors:  David G Sweet; Virgilio Carnielli; Gorm Greisen; Mikko Hallman; Eren Ozek; Arjan Te Pas; Richard Plavka; Charles C Roehr; Ola D Saugstad; Umberto Simeoni; Christian P Speer; Maximo Vento; Gerhard H A Visser; Henry L Halliday
Journal:  Neonatology       Date:  2019-04-11       Impact factor: 4.035

3.  Lipopolysaccharide-induced acute lung injury in rats: comparative assessment of intratracheal instillation and aerosol inhalation.

Authors:  Fangfang Liu; Wenli Li; Jürgen Pauluhn; Hubert Trübel; Chen Wang
Journal:  Toxicology       Date:  2013-01-08       Impact factor: 4.221

4.  Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro.

Authors:  Guido Stichtenoth; Philipp Jung; Gabi Walter; Jan Johansson; Bengt Robertson; Tore Curstedt; Egbert Herting
Journal:  Pediatr Res       Date:  2006-03       Impact factor: 3.756

5.  SP-A permeabilizes lipopolysaccharide membranes by forming protein aggregates that extract lipids from the membrane.

Authors:  Olga Cañadas; Ignacio García-Verdugo; Kevin M W Keough; Cristina Casals
Journal:  Biophys J       Date:  2008-07-03       Impact factor: 4.033

6.  Polymyxin B agonist capture therapy for intrauterine inflammation: proof-of-principle in a fetal ovine model.

Authors:  Masatoshi Saito; Matthew S Payne; Yuichiro Miura; Demelza J Ireland; Sarah Stock; Suhas G Kallapur; Paranthaman S Kannan; John P Newnham; Boris W Kramer; Alan H Jobe; Jeffrey A Keelan; Matthew W Kemp
Journal:  Reprod Sci       Date:  2013-11-12       Impact factor: 3.060

7.  Pulmonary surfactant preserves viability of alveolar type II cells exposed to polymyxin B in vitro.

Authors:  Guido Stichtenoth; Egbert Herting; Mario Rüdiger; Andreas Wemhöner
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

8.  The Perturbation of Pulmonary Surfactant by Bacterial Lipopolysaccharide and Its Reversal by Polymyxin B: Function and Structure.

Authors:  Maros Kolomaznik; Gilda Liskayova; Nina Kanjakova; Lukas Hubcik; Daniela Uhrikova; Andrea Calkovska
Journal:  Int J Mol Sci       Date:  2018-07-05       Impact factor: 5.923

9.  SP-D attenuates LPS-induced formation of human neutrophil extracellular traps (NETs), protecting pulmonary surfactant inactivation by NETs.

Authors:  Raquel Arroyo; Meraj Alam Khan; Mercedes Echaide; Jesús Pérez-Gil; Nades Palaniyar
Journal:  Commun Biol       Date:  2019-12-16

Review 10.  Postnatal Infections and Immunology Affecting Chronic Lung Disease of Prematurity.

Authors:  Gloria S Pryhuber
Journal:  Clin Perinatol       Date:  2015-10-01       Impact factor: 3.430

View more
  1 in total

1.  Cooperative action of SP-A and its trimeric recombinant fragment with polymyxins against Gram-negative respiratory bacteria.

Authors:  Juan Manuel Coya; Víctor Fraile-Ágreda; Lidia de Tapia; Belén García-Fojeda; Alejandra Sáenz; José A Bengoechea; Nina Kronqvist; Jan Johansson; Cristina Casals
Journal:  Front Immunol       Date:  2022-09-07       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.